Use of Insulin Pump Therapy in the Pediatric Age-Group Consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes

Indiana University-Purdue University Indianapolis, Indianapolis, Indiana, United States
Diabetes care (Impact Factor: 8.42). 07/2007; 30(6):1653-62. DOI: 10.2337/dc07-9922
Source: PubMed
Download full-text


Available from: Thomas Danne
  • Source
    • "1 [0] [1] [6] 2,5 [0] [9] "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is an increase in the incidence of type 1 diabetes (T1D) in children younger than 5 years of age and continuous subcutaneous insulin infusion (CSII) appears to be an increasingly popular therapeutic option in France. A retrospective self-evaluation questionnaire was distributed to parents of young children with T1D treated by CSII (42 children, age 4.8±1.0 years, 2.3±0.5 years at the onset of TD1, mean± SD). It focused on the quality of diabetes management in daycare centers or with nannies and at school. Parental satisfaction related to the management of their children was overall good (84% for all the parents, 70.5% for the parents of children at nursery-school, from 3 to 6 years. However 93% of the parents experienced and overcame serious difficulties: exclusion of the children on account of DT1 (school trips, daycare centers after school), use of the pump for lunch and snacks, realization of glycemic controls, participation in school trips, survey during school meals. In spite of these difficulties these young children had a normal and safe time at school. The management of the young children with DT1, treated by CSII, in alternate care centers and at school need to be improved; the experience was positive when daycare workers and teachers agreed to be instructed.
    Full-text · Article · Dec 2013 · Archives de Pédiatrie
  • Source
    • "It is currently considered to be the optimal method of insulin administration, since it imitates the pancreatic activity in the best possible way, ensures precise dosage, and at the same time offers a high level of ease and comfort. Patients that experience the advantages are above all children and adolescents with type 1 diabetes mellitus (T1DM) [1] [2] [3]. Compared to the traditional methods of insulin therapy by means of multiple daily insulin injections (MDI), CSII can significantly decrease glycated hemoglobin (HbA 1 C), reduce 24-hour glucose variability, decrease incidence of severe hypoglycemia, and eliminate dawn phenomenon. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Assessment of the effect of a treatment method change from multiple daily insulin injection (MDI) to continuous subcutaneous insulin infusion (CSII) on the development of early angiopathy in children with T1DM with or without retinopathy. Methods: The study pump group involved 32 diabetic children aged 14.8, with the initial HbA1c level of 8.3%, previously treated by MDI. The patients were examined before pump insertion and after 3 and 6 months of CSII. We assessed HbA1c level, carotid artery intima-media thickness (c-IMT), and flow-mediated dilatation (FMD) of the brachial artery. The pump group was compared to a group of eight teenagers with diagnosed nonproliferative retinopathy, treated with MDI. Results: HbA1c in the entire group was found to improve in the second and in the third examination. During 6 months of CSII, FMD increased and IMT decreased. Retinopathic adolescents had significantly thicker IMT and lower FMD compared to baseline results of the pump group. Treatment intensification in the retinopathy-free children enhanced these differences. Conclusions: CSII is associated with lower IMT and higher FMD. Whether on the long-run CSII is superior to MDI to delay the occurrence of diabetes late complications remains to be explained.
    Full-text · Article · Nov 2013 · Mediators of Inflammation
  • Source
    • "demonstrating high motivation and an ability to follow an intense regimen (Cogen, Streisand, & Sarin, 2002; Phillip et al., 2007), which may be difficult to sustain once the goal of initiating CSII is achieved and its novelty diminishes (Danne et al., 2008). The present study, utilized a sample of adolescents with a range of experience on CSII (pump duration .01 "
    [Show abstract] [Hide abstract]
    ABSTRACT: To examine pump duration associations with adolescents' metabolic control and whether parental involvement moderated this association. This study used a cross-sectional sample of 10- to 14-year-olds with diabetes (N = 252, 53.6% female) and parents' reported parental involvement; HbA1c was obtained from medical records. Half (50.8%) were on an insulin pump (continuous subcutaneous insulin infusion, CSII), with the remainder prescribed multiple daily injections (MDI). Adolescents on CSII displayed better HbA1c than those on MDI. A curvilinear association revealed that participants on CSII for <2 years showed a positive pump duration-HbA1c association, while those on CSII longer showed no association. Parental involvement interacted with pump duration to predict HbA1c. Pump duration was associated with poorer HbA1c only when parents were relatively uninvolved. Within the limitations of a cross-sectional design, data suggest that adolescents on CSII have better HbA1c than those on MDI, but may experience a period of deterioration that can be offset by parental involvement.
    Full-text · Article · Mar 2010 · Journal of Pediatric Psychology
Show more